GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...

Despite the boost to contributions, WHO has downsized its 2026-27 budget by over $1bn due to financial constraints.

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...

The US Food and Drug Administration (FDA) is set to restrict the Covid-19 booster doses to older adults and those at risk of ...

The US Department of Health and Human Services (HHS) said it is “taking immediate steps” to implement a recent Executive ...

The 5th Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) will gather industry leaders in Vösendorf, Austria on ...

Companies remain exposed to heightened risks between the world’s largest markets and are cautious of the stability of ...

The London Biotechnology Show returns for its highly anticipated second edition, building on the remarkable success of its ...

All participants will initially undergo a run-in period on standardised medium-dose ICS/LABA to confirm persistent lack of ...

The agreement will see international initiatives to fight the next pandemic, but funding remains the weak link.

The Japanese MHLW has granted approval for the use of GSK’s Blenrep (belantamab mafodotin) combinations for MM.

Data presented at ATS 2025 showed that lung improvement in paediatric cystic fibrosis (CF) patients receiving ETI therapy is ...